Siemens Healthineers AG

HOUSTON, Nov. 18, 2024 /PRNewswire/ -- Echolight, a global innovator in bone densitometry, announced that it has signed an agreement enabling Siemens Healthineers to be a reseller of Echolight bone densitometers in support of their Women's Health solutions. Continue Reading EchoStation from Echolight Medical Echolight's REMS (Radiofrequency Echographic Multi Spectometry) innovative technology measures bone density and microarchitecture without using the radiation of traditional x-ray scans but instead through a simple ultrasound scan of axial anatomical sites such as the spine and femur. This radiation-free technology allows physicians to perform repeated scans for monitoring bone health over time. In addition, the ability to automatically exclude artifacts commonly present with other densitometry procedures yields a highly reliable diagnostic assessment. "Bone health is a serious problem here in the US. This agreement provides expanded provider and patient access to REMS technology in the US through ultrasound-based bone density scanning as another option in the effort to diagnose and monitor bone health. Echolight is pleased to support Siemens Healthineers in their focus on women's health and bone disease," explained Thomas J. McLaughlin, Executive Commercial Director, Echolight USA. Echolight's portable solution measures bone quantity and quality simultaneously, through evaluation of bone mineral density at the lumbar vertebrae (L1-L4) and the femoral neck providing all common parameters of the diagnosis of osteoporosis BMD (g/cm2), T-scores, and Z-score. It also measures fragility score through an independent assessment of internal bone structure to evaluate the risk of fracture in 5 years through dedicated statistical and spectral analysis. Siemens Healthineers will be offering the Echos Plus, Echostation, and Echohybrid Plus models. For more information, visit the Echolight booth #1853 at the RSNA Annual Meeting. Echolight was established in Italy with head office in Lecce, and in 2020 opened its offices in the United States. Since then, its sales network has grown to more than 40 distributors and several hundreds of satisfied customers across the world who have adopted the innovative R.E.M.S. technology for assessing the bone condition of their patients. Created as a spin-off of the Italian National Research Council, Echolight is at the forefront of medical innovation, introducing new cutting-edge solutions to contribute to human wellbeing. It has been awarded all the standard certificates: UNI CEI EN ISO 13485: 2016, Quality Management System UNI EN ISO 9001: 2015, CE mark, FDA clearance, and other major certificates worldwide for innovative solutions considered as the best practice in bone health for personalized medicine. SOURCE Echolight Medical WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

The growing prevalence of cardiovascular and thrombotic disorders is driving strong demand for D-dimer testing. As blood clot-related risk factors continue to increase, the need for precise diagnostic tools becomes essential. Moreover, intensified research and development efforts, coupled with collaborations among major industry players, are propelling innovations in D-dimer testing methods. LAS VEGAS, Nov. 11, 2024 /PRNewswire/ -- DelveInsight's D-Dimer Testing Market Insights report provides the current and forecast market analysis, individual leading D-dimer testing companies' market shares, challenges, D-dimer testing market drivers, barriers, trends, and key market D-dimer testing companies in the market. Key Takeaways from the D-Dimer Testing Market Report As per DelveInsight estimates, North America is anticipated to dominate the global D-dimer testing market during the forecast period. In the D-dimer testing market, the instruments category is projected to capture a substantial revenue share in 2023. Notable D-dimer testing companies such as F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Abbott, Danaher Corporation, biomérieux, QuidelOrtho Corporation, Thermo Fisher Scientific Inc., CTK Biotech, Getein Biotech, Inc., LumiraDx, Accurex, Werfen, Randox Laboratories Ltd., Sekisui Diagnostics, Laboratory Corporation of America Holdings, Helena Laboratories (UK) Limited, BioMedica Diagnostics, Diazyme Laboratories, Inc., HORIBA, Ltd., Sysmex Corporation, and several others, are currently operating in the D-dimer testing market. In June 2022, LumiraDx Limited, a next-generation point-of-care diagnostics company, announced that it has expanded its cardiovascular offering with a CE Mark for its new NT-proBNP test to aid in the diagnosis of CHF and an updated CE Mark for its D-dimer test to now rule out venous thromboembolism (VTE) in symptomatic patients. In March 2022 SphingoTec GmbH and Rivaara Labs Pvt Ltd. announced that they have entered into a multi-year distribution agreement for the commercialization of SphingoTec's point-of-care diagnostic solutions in the Indian subcontinent. The Nexus IB10 analyzer and its portfolio of rapid tests allow convenient assessment of biomarkers relevant to critical care conditions such as sepsis, acute kidney injury, cardiogenic shock, acute heart failure, and myocardial infarction. To read more about the latest highlights related to the D-dimer testing market, get a snapshot of the key highlights entailed in the Global D-Dimer Testing Market Report D-Dimer Testing Overview D-dimer testing is a blood test used to detect the presence of abnormal blood clotting, often aiding in the diagnosis of conditions related to thrombosis, such as deep vein thrombosis (DVT), pulmonary embolism, and disseminated intravascular coagulation (DIC). The D-dimer is a protein fragment produced when a blood clot dissolves in the body, and elevated levels of D-dimer indicate an increased presence of clot degradation, suggesting active clotting and fibrinolysis. This test is particularly useful in ruling out conditions rather than confirming them, as a negative D-dimer test strongly suggests the absence of thrombotic events, especially in low-risk patients. While the D-dimer test is highly sensitive, it lacks specificity because elevated D-dimer levels can be found in various conditions, including recent surgery, infection, cancer, and pregnancy. Due to this, a positive D-dimer test alone is insufficient for a definitive diagnosis of a clotting disorder and usually requires further imaging or diagnostic tests to confirm the presence of a clot. Despite these limitations, the D-dimer test remains a valuable and accessible tool in emergency and outpatient settings, especially in rapidly assessing patients suspected of having thrombotic conditions. Its utility in conjunction with clinical assessment helps healthcare providers make timely and more accurate decisions about further testing or treatment. D-Dimer Testing Market Insights In 2023, North America led the D-dimer testing market, propelled by several key factors. The region faces a high prevalence of cardiovascular and thrombotic disorders, which drives significant demand for diagnostic tools like D-Dimer tests. An aging population in North America, particularly susceptible to these conditions, further underscores the need for reliable testing solutions. Moreover, North America's robust healthcare infrastructure ensures broad access to advanced diagnostic technologies, supporting a higher testing rate. This infrastructure also enhances awareness among healthcare providers about the critical role of D-dimer testing in diagnosing conditions such as deep vein thrombosis (DVT) and pulmonary embolism. Technological advancements are central to this market, with innovations in D-dimer assays and testing instruments improving both accuracy and efficiency. The presence of prominent pharmaceutical and diagnostic firms in the region also boosts research and development, resulting in frequent product releases and regulatory approvals. Additionally, favorable reimbursement policies and high healthcare spending in North America encourage wider adoption of D-dimer testing. The focus on rapid diagnosis and effective management of thromboembolic conditions, especially in emergency and critical care, further supports market growth. In essence, a combination of high thrombotic disorder prevalence, an aging demographic, advanced healthcare infrastructure, ongoing technological progress, and supportive reimbursement policies makes North America the dominant region in the D-dimer testing market. The pressing need for effective diagnostics amid rising cardiovascular risks reinforces this trend. To know more about why North America is leading the market growth in the D-dimer testing market, get a snapshot of the D-Dimer Testing Market Outlook D-Dimer Testing Market Dynamics The D-dimer testing market has seen significant growth in recent years, driven largely by the increasing prevalence of thrombotic disorders such as deep vein thrombosis (DVT) and pulmonary embolism, which are major contributors to morbidity and mortality worldwide. The aging global population, which is more prone to conditions requiring D-dimer testing, has also spurred demand in the market. A substantial boost to the D-dimer testing market occurred during the COVID-19 pandemic, as the test became a valuable tool in managing COVID-19 patients. Elevated D-dimer levels were found to be associated with severe COVID-19 cases, prompting widespread usage of the test to monitor patients' risk of blood clots and severe outcomes. This expanded its application and highlighted the utility of D-dimer testing beyond traditional thrombotic disorders, thereby broadening its market scope. As healthcare systems continue to deal with the long-term impact of COVID-19, the demand for D-dimer testing remains strong. Technological advancements in diagnostic testing have also influenced the D-dimer testing market dynamics. Innovations such as point-of-care (POC) testing devices have made D-dimer tests more accessible, enabling rapid results outside traditional laboratory settings. This shift toward decentralizing testing is especially beneficial in remote and underserved areas, where access to comprehensive healthcare facilities might be limited. Additionally, the integration of artificial intelligence and data analytics in diagnostic processes is improving test accuracy and enabling more precise predictive insights, adding value to D-dimer testing solutions. However, challenges remain in the market, particularly in terms of test specificity. While D-dimer tests are sensitive indicators of clot formation, they are not highly specific and can yield false positives, as D-dimer levels can be elevated in other conditions, such as infections, inflammation, and even after surgery. This limitation means that D-dimer testing is often used as a preliminary diagnostic tool rather than a definitive test. Consequently, reliance on confirmatory imaging tests, such as CT scans or ultrasounds, continues to persist, which can slow down diagnosis and add costs, especially in resource-constrained settings. Looking forward, the D-dimer testing market is likely to expand as new applications for the test emerge and technological advancements improve its accuracy and accessibility. With the rising prevalence of cardiovascular and thrombotic conditions, coupled with the lingering effects of the COVID-19 pandemic, healthcare providers and diagnostic companies are likely to invest in improving D-dimer testing. Strategic partnerships and collaborations between diagnostic firms and healthcare institutions may further drive market growth by making testing more accessible and affordable. As a result, the D-dimer testing market is expected to maintain a robust growth trajectory in the coming years, especially in regions with high healthcare expenditures and advanced medical infrastructure. Get a sneak peek at the D-dimer testing market dynamics @ D-Dimer Testing Market Dynamics Analysis D-Dimer Testing Market Assessment D-Dimer Testing Market Segmentation D-Dimer Testing Market Segmentation By Product Type: Instruments and Reagents and Kits D-Dimer Testing Market Segmentation By Assay Type: Enzyme-linked Immunosorbent Assay (ELISA), Latex Immunoturbidimetric Assay, Fluorescence Immunoassay, and Others D-Dimer Testing Market Segmentation By Application: Deep Vein Thrombosis (DVT), Pulmonary Embolism, Disseminated Intravascular Coagulation (DIC), and Stroke D-Dimer Testing Market Segmentation By End User: Hospitals and Clinics, Diagnostic Centers, and Others D-Dimer Testing Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the D-dimer testing market are set to emerge as the trendsetter explore @ D-Dimer Testing Companies Table of Contents Interested in knowing the D-dimer testing market by 2030? Click to get a snapshot of the D-Dimer Testing Market Trends Related Reports ELISA Market ELISA Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key ELISA companies, including Abbott, F. Hoffmann-La Roche Ltd, Erba Mannheim, Synbiotik, Maccura Biotechnology Co., Ltd., Thermo Fisher Scientific, DiaSorin, PerkinElmer Inc., Diatron, Werfen, ALPCO, Agilent, InBios International Inc., Awareness Technology Inc., Elabscience Biotechnology Inc., J. Mitra & Co. Pvt. Ltd., Rayto Life and Analytical Sciences Co., Ltd., BD, Trivitron Healthcare, among others. Deep Vein Thrombosis Market Deep Vein Thrombosis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key DVT companies, including Carbomimetics, GlycoMimetics, Marizyme, Boehringer Ingelheim, Bio-Synectics, Inc., among others. Pulmonary Embolism Market Pulmonary Embolism Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key pulmonary embolism companies, including Translational Sciences, Supergene, Angde Biotech Pharmaceutical, Yuhan, among others. Disseminated Intravascular Coagulation Market Disseminated Intravascular Coagulation Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key DIC companies, including Pfizer Inc., Hoffmann-La Roche Ltd., Siemens Healthineers, Abbott Laboratories, Sysmex Corporation, Nihon Kohden Corporation, Thermo Fisher Scientific Inc., Danaher Corporation, Grifols, S.A., Beckman Coulter Inc., among others. About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

NEW YORK, Oct. 16, 2024 /PRNewswire/ -- According to The Insight Partners study on the Radiation Oncology Market is observing significant growth owing to the increasing prevalence of cancer. The report runs an in-depth analysis of market trends, key players, and future opportunities. In general, the radiation oncology market consists of different products that are expected to contribute to market growth in the coming years. Download Sample Report: Overview of Report Findings 1. Market Growth: The radiation oncology market is expected to reach US$ 23.62 billion by 2031 from US$ 8.92 billion in 2023; it is anticipated to register a CAGR of 13.0% from 2023 to 2031. Radiation oncology is the specialized medical treatment of cancer using radiation therapy. Radiation oncology is high-energy radiation therapy with X-rays or high energy particles to kill cancer cells or shrink tumors. Radiation oncologists coordinate with other healthcare workers to identify a suitable personalized treatment plan, which depends on factors such as the nature, site, and stage of the cancer and the patient's general condition. Treatment can be done internally in the form of brachytherapy or externally through radiation, known as external beam therapy. 2. Cancer is one of the common health conditions significantly impacting societies worldwide. According to the World Health Organization (WHO), it is the leading cause of death across the world; it was the cause of 20 million new cancer cases and 9.7 million deaths in 2022. The number of new cancer cases is further expected to reach ~35 million new cancer cases by 2050. As per the WHO 2024 report, lung cancer is the most common cause of mortality globally, followed by colorectal cancer, liver cancer, breast cancer, and stomach cancer, which are responsible for 18.7%, 9.3%, 7.8%, 6.9%, and 6.8% of the total cancer related deaths, respectively. The incidences of the top 10 cancer types are mentioned in the table below. Figure 1. Statistics at Glance, Global, 2022 Source: Global Cancer Observatory The increasing incidence of cancer results in a huge demand for effective treatment options. Radiotherapy is one of the continuously evolving treatment options with effective outcomes for cancer patients. The method of intervention utilizes high doses of radiation such as X-rays and gamma rays to kill cancer cells. Radiation therapy is mainly prescribed in patients with the early stages of cancer, while it can also be used at any point in the treatment. Various types of external beam radiotherapy are used for the treatment of different cancer types. For instance, brachytherapy is used for the treatment of breast cancer, cervix cancer, eye cancer, prostate cancer, and head & neck cancer. Further, systemic radiation therapy, also known as radioactive iodine therapy, is used for the treatment of thyroid cancer. Thus, the increasing prevalence of cancer and the evolution of radiotherapy in oncology bolsters the radiation oncology market growth. 3. Technological Advancements in Radiation Oncology: Radiotherapy focuses on destroying cancerous cells, with the maximum possibility of sparing healthy cells, which was achieved over a period with continuous advancements in imaging technologies such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET). These imaging technologies, combined with developments in 3D conformal radiotherapy, help identify tumor cells and provide information on their exact position and size. Trending radiation therapies that signify developments in radiotherapy technologies are mentioned below: Flash Therapy: Flash therapy is being investigated for safety and effectiveness. Unlike earlier approaches that require dose administration over multiple days or weeks, this therapy involves delivering the entire dose of massive radiation at once very quickly. Healthy cells recover well with time, killing only cancer cells. Identify the Key Trends Affecting This Market - Download Sample PDF: Image-guided radiation therapy (IGRT): This technology allows for the real-time imaging of tumors and their surrounding healthy tissues before each treatment session, ensuring that the radiation beams are accurately targeted at the tumors and minimizing damage to nearby organs. Intensity-modulated radiation therapy (IMRT): IMRT allows for the delivery of varying intensities of radiation to different parts of the tumor, allowing for better dose distribution and sparing of healthy tissue. Stereotactic body radiation therapy (SBRT): SBRT involves delivering high doses of radiation to small, well-defined tumors in a limited number of treatment sessions, leading to better local control of a tumor. Proton therapy: Proton therapy uses protons instead of traditional X-rays to deliver radiation to the tumor, allowing for more precise targeting of the tumor and sparing of healthy tissue. Adaptive radiation therapy: This technology allows for adjustments to the treatment plan based on changes in the tumor size or position during treatment, ensuring that the radiation dose is continuously optimized for maximum effectiveness. Artificial intelligence (AI) is also being incorporated into cancer treatment for treatment planning, CT scan image labeling, and other applications. Additionally, various types of radiation therapy equipment are integrated with AI to benefit patients and healthcare professionals alike. In March 2024, RefleXion Medical, Inc. and Limbus AI, Inc. collaborated for the integration of Limbus Contour (AI driven solution), into the RefleXion X1 radiotherapy treatment planning system. This integration will reduce the most significant bottleneck in the patient treatment planning process, which involves delineating the tumor target from surrounding critical organs and other healthy tissue. Therefore, developments in radiotherapy technologies and the increasing integration of artificial intelligence to support more controlled and quicker treatments are expected to bring new growth trends in the radiation oncology market in the coming years. 4. Geographical Insights: In 2023, Asia Pacific led the market with a substantial revenue share, followed by North America and Europe. Asia Pacific is expected to register the highest CAGR during the forecast period. Market Segmentation Based on type, the radiation oncology market is bifurcated into external beam radiation therapy and internal beam radiation therapy. The external Beam radiation therapy segment is subsegmented into 3D conformal radiotherapy, stereotactic technology, proton beam therapy, and others. The internal beam radiotherapy segment is subsegmented into brachytherapy, systemic beam radiation therapy, and others. The external beam radiotherapy segment held a larger share of the market in 2023. By application, the radiation oncology market is segmented into breast cancer, prostate cancer, lung cancer, head and neck cancer, cervical cancer, and others. The breast cancer segment dominated the market in 2023. The radiation oncology market is segmented into five major regions: North America, Europe, APAC, Middle East & Africa, and South & Central America. Purchase Premium Copy of Global Radiation Oncology Market Growth Report (2021-2031) at: Competitive Strategy and Development Key Players: Major companies operating in the radiation oncology market include Varian Medical Systems Inc, Elekta AB, Accuracy Incorporated, IBA Worldwide (Ion Beam Applications SA), Becton Dickinson & Co, Perspective Therapeutics Inc, Nordion, Mevion Medical Systems, NTP Radioisotopes, and Mallinckrodt Plc. Trending Topics: Personalized medicine, Radiomics, stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) techniques, and combining radiation therapy with immunotherapy, among others. Headlines on Radiation Oncology "Varian has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), as well as CE mark, for Halcyon and Ethos radiotherapy systems." "Varian has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for TrueBeam and Edge radiotherapy systems." "Atlantic Health System and Mevion Medical Systems announced Atlantic Health System's plans to acquire and install a MEVION S250-FIT Proton Therapy System." "Accuray Incorporated entered agreement with TrueNorth Medical Physics LLC to provide radiation oncology departments with third-party support designed to enhance their department's capabilities." "Curium extended its current partnership with NRG I PALLAS for new irradiation services in Petten, Netherlands to produce non-carrier added lutetium-177 (Lu-177)." Obtain Analysis of Key Geographic Markets - Download Report PDF: North America, particularly the U.S., holds a dominant position in the global radiation oncology market. The combination of well-established healthcare infrastructure, high healthcare spending, and an advanced pool of radiation oncology professionals makes the region a key player in driving growth. The projected compound annual growth rate (CAGR) of 12.6% from 2023 to 2031 suggests that North America will continue to lead the market in the coming years, with ongoing support from healthcare authorities and institutions. Overall, with increasing investments in research and development, advancements in technology, and support from both public and private sectors, the radiation oncology market is on a solid growth trajectory, playing a vital role in the ongoing fight against cancer. Conclusion The increasing prevalence of cancer and the rising initiatives to support development in radiation oncology are driving the growth of the radiation oncology market. Key trends such as integration of artificial intelligence and radiomics, developing techniques like stereotactic body radiotherapy ushering in effective, targeted, and simplified treatments for different types of cancer. The growing integration between radiation therapy and immunotherapy is opening new avenues for better efficacy against different types of cancers. In addition, improved access and experience for patients are offered by telemedicine and remote monitoring. Overall, the radiation oncology market is quite promising because research and development, which are already underway, are likely to further elaborate on treatment modalities for enhancing patient outcomes as well as the access rate to care. Therefore, the above-mentioned trends are going to evolve and will play a much more crucial role in changing the scenario in the future as far as cancer treatment is concerned. The report from The Insight Partners, therefore, provides several stakeholders—including radiation oncology equipment manufacturers, radiation oncology systems distributors, and others—with valuable insights into how to successfully navigate this evolving market landscape and unlock new opportunities. Require A Diverse Region or Sector? Customize Research to Suit Your Requirement: The radiation oncology market is categorized based on treatment types and applications. In terms of treatment types, the market is divided into external beam radiation therapy and internal beam radiation therapy. In 2023, external beam radiation therapy held a larger market share due to its widespread use and well-established role in cancer treatment. However, the internal beam radiation therapy segment, which involves the direct delivery of radiation to the tumor site through sources placed inside the body, is expected to register a higher compound annual growth rate (CAGR) during the period from 2023 to 2031. This growth can be attributed to its increasing use in certain cancers and its ability to provide targeted therapy with reduced damage to surrounding healthy tissues. Related Report Titles: Breast Cancer Diagnostics Market Size and Forecasts 2021 - 2031 Liver Cancer Diagnostics Market Analysis, Size, Share, Growth, Trends, and Forecast by 2031 Pancreatic Cancer Therapy Market Report 2031 Peptide Cancer Vaccine Market Size and Forecasts 2021 – 2031 Prostate Cancer Devices Market Size and Forecasts 2021 – 2031 Lung Cancer Market Size and Forecasts 2021 – 2031 Overhead Cranes Market Growth, Size, Share, Trends, Key Players Analysis, and Forecast till 2031 Cervical Cancer Diagnostic Tests Market Size and Forecasts 2021 - 2031 About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact Us: If you have any queries about this report or if you would like further information, please contact us: Contact Person: Ankit Mathur E-mail: [email protected] Phone: +1-646-491-9876 Press Release: Logo: SOURCE The Insight Partners WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED